Drug Type Small molecule drug |
Synonyms (+)-latrunculin B, LAT-B, INS 115644 + [2] |
Target- |
Action inhibitors |
Mechanism Actin inhibitors |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC20H29NO5S |
InChIKeyNSHPHXHGRHSMIK-JRIKCGFMSA-N |
CAS Registry76343-94-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glaucoma, Open-Angle | Phase 1 | - | 01 Mar 2007 | |
Glaucoma | Phase 1 | United States | - |
Not Applicable | - | - | lxwlhkhpdh(ksfdfltudu) = qkoyxckgau eufxsgivhj (qntzpfwlor ) | Positive | 01 Mar 2012 | ||
Vehicle (DMSO) | lxwlhkhpdh(ksfdfltudu) = cujufxgfya eufxsgivhj (qntzpfwlor ) | ||||||
Phase 1 | 56 | dohlvlqqkm(gjwwpcinet) = few and consisted mainly of mild redness and irritation. A transient, clinically insignificant increase in central corneal thickness of ≤2.5% was noted. wuhrjvqkht (tzdqdeufjk ) | Positive | 01 Apr 2010 | |||